Positive dupixent® (dupilumab) phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in the lancet

Dupixent is the first and only biologic that significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old in a phase 3 trial published results reinforce well-established efficacy and safety profile of dupixent across age groups tarrytown, n.y. and paris , sept.
REGN Ratings Summary
REGN Quant Ranking